SAN FRANCISCO (Thomson Financial) - Human Genome Sciences Inc. late Monday
reported a first-quarter net loss of $46.9 million, or 35 cents a share, versus
$51 million, or 38 cents a share, a year earlier.
The mean estimate of analysts polled by Thomson Reuters was a per-share loss
of 19 cents.
Revenue for the quarter ended March 31 rose to $12.3 million from $9.26
million in the year-ago period, versus the mean Street view of $15 million.
Net cash burn in 2008 remains on track for the previously issued guidance of
$135 million to $155 million, the Rockville, Md.-based pharmaceutical company
said. Human Genome Sciences believes it is possible GlaxoSmithKline will reach a
decision in 2008 regarding whether to advance Syncria to Phase III development.
The stock closed the regular session up 4 cents at $6.63 but fell 5.3% to
$6.28 in after-hours trading.
Brigid Gaffikin
bg/gm
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|